IL-SKZG-260001 Jan2026

Indications:^6-7
SKYRIZI
Skyrizi 360mg and 600mg are indicated for the treatment of patients 16 years and older with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy, or if such therapies are not advisable. 
Skyrizi 180mg, 360mg and 600mg are indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

RINVOQ
RINVOQ 15 MG/RINVOQ 30 MG/RINVOQ 45 MG is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. 
RINVOQ 15 MG/RINVOQ 30 MG/RINVOQ 45 MG is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent

1.Noor N, et al. Lancet Gastroenterol Hepatol. 2024. S2468–53(24)00034–7. 2. Colombel JF, et al. Lancet. 2017;390:2779–89. 3. Colombel JF, et al. Gastroenterology. 2017;152:351–61; 4.Pariente B, et al. Inflamm Bowel Dis. 2011;17:1415–22. 5. Khanna R, et al. Clin Gastroenterol Hepatol. 2022;20:727–36.e2. 6. Skyrizi prescribing information 7. Rinvoq prescribing information